IOL Chemicals and Pharmaceuticals
Other · 1 quarter tracked · source-linked performance and management context.
Latest revenue
₹580 Cr
verified financial record
Quarters tracked
1
source records in the directory
Delivery assessment
Unscored
No scored management commitments are present yet.
Call date
2026-02-10
latest available source date
Signal trajectory
1 actual quarterCurrent read
Unscored
No scored management commitments are present yet.
Latest source read
What changed this quarter?
IOL Chemicals reported Q3 FY26 revenue of ₹580 crore (+10.9% YoY) and EBITDA of ₹62.6 crore (+22.8% YoY), with EBITDA margin expanding 100 bps to 10.7%. Pharma segment contributed 61% of revenue, driven by ibuprofen (64% of pharma) and non-ibuprofen APIs (36%). Chemicals ran at near 100% capacity. Management guided for ₹600 crore revenue in Q4 and 10-15% top-line growth in FY27, with EBITDA margin improvement of 1-2% in Q4. However, elevated fuel costs (rice husk) and paracetamol underutilization (60% capacity) pressured margins. The company targets a 50/50 revenue mix between ibuprofen and non-ibuprofen APIs over two years. Key risk: sustained high fuel costs could delay margin recovery.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Watch
Revenue
₹580 Cr
Source date
2026-02-10
Across the record
Quarter history.
History modules